{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:17:04Z","timestamp":1784945824314,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-024-03823-w","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T07:14:49Z","timestamp":1735629289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-6503","authenticated-orcid":false,"given":"Kannan","family":"Sridharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"3823_CR1","doi-asserted-by":"publisher","first-page":"1015338","DOI":"10.3389\/fphar.2022.1015338","volume":"13","author":"L Zhou","year":"2022","unstructured":"Zhou L, Zhan W, Wei X. Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. Front Pharmacol. 2022;13:1015338.","journal-title":"Front Pharmacol"},{"issue":"5","key":"3823_CR2","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","volume":"31","author":"E Ricciotti","year":"2011","unstructured":"Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986\u20131000.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3823_CR3","unstructured":"Tripathy K, Patel P, Geetha R, Latanoprost. 2024 Feb 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan\u2013. PMID: 31082022."},{"issue":"3","key":"3823_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0002-9394(99)00160-9","volume":"128","author":"SS Hayreh","year":"1999","unstructured":"Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol. 1999;128(3):301\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"3823_CR5","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1167\/iovs.05-1253","volume":"47","author":"L Quaranta","year":"2006","unstructured":"Quaranta L, Gandolfo F, Turano R, Rovida F, Pizzolante T, Musig A, Gandolfo E. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47(7):2917\u201323.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3823_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2174\/1874364101711010305","volume":"11","author":"A Vaajanen","year":"2017","unstructured":"Vaajanen A, Vapaatalo H. A single Drop in the Eye - effects on the whole body? Open Ophthalmol J. 2017;11:305\u201314.","journal-title":"Open Ophthalmol J"},{"key":"3823_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2147\/OPTH.S44708","volume":"8","author":"K Inoue","year":"2014","unstructured":"Inoue K. Managing adverse effects of glaucoma medications. Clin Ophthalmol. 2014;8:903\u201313.","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"3823_CR8","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/j.bjoms.2011.07.021","volume":"50","author":"AM Gruener","year":"2012","unstructured":"Gruener AM, Griffiths MF. Increased systemic side effects of prostaglandin analogue eye drops in patients with palatal defects. Br J Oral Maxillofac Surg. 2012;50(3):e45.","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"5","key":"3823_CR9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1248\/bpb.b16-00848","volume":"40","author":"K Ohyama","year":"2017","unstructured":"Ohyama K, Kawakami H, Inoue M. Blood pressure Elevation Associated with Topical Prostaglandin F2\u03b1 analogs: an analysis of the different spontaneous adverse event report databases. Biol Pharm Bull. 2017;40(5):616\u201320.","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"3823_CR10","first-page":"420","volume":"10","author":"MA Khaleel","year":"2022","unstructured":"Khaleel MA, Khan AH, Ghadzi SMS, Adnan AS, Abdallah QM. A standardized dataset of a spontaneous adverse event reporting system. Healthc (Basel). 2022;10(3):420.","journal-title":"Healthc (Basel)"},{"key":"3823_CR11","unstructured":"FDA Adverse Event Reporting System (FAERS) Public Dashboard. Available at: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard (Accessed on July 27, 2024)."},{"key":"3823_CR12","unstructured":"FDA Adverse Event Reporting System (FAERS). Electronic Submissions. Available at: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-electronic-submissions (Accessed on October 11, 2024)."},{"issue":"2","key":"3823_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL. Case-non-case studies: Principle, methods, bias and interpretation. Therapie. 2019;74(2):225\u201332.","journal-title":"Therapie"},{"key":"3823_CR14","doi-asserted-by":"publisher","unstructured":"Poluzzi E, Raschi E, Piccinni C, De F. Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS) [Internet]. Data Mining Applications in Engineering and Medicine. InTech; 2012. Available from: https:\/\/doi.org\/10.5772\/50095","DOI":"10.5772\/50095"},{"issue":"23","key":"3823_CR15","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1002\/1097-0258(20001215)19:23<3199::AID-SIM621>3.0.CO;2-Q","volume":"19","author":"SJ Evans","year":"2000","unstructured":"Evans SJ. Pharmacovigilance: a science or fielding emergencies? Stat Med. 2000;19(23):3199\u2013209.","journal-title":"Stat Med"},{"key":"3823_CR16","doi-asserted-by":"publisher","first-page":"106315","DOI":"10.1016\/j.ejps.2022.106315","volume":"180","author":"K Asendrych-Wicik","year":"2023","unstructured":"Asendrych-Wicik K, Zarczuk J, Walaszek K, Ciach T, Markowicz-Piasecka M. Trends in development and quality assessment of pharmaceutical formulations - F2\u03b1 analogues in the glaucoma treatment. Eur J Pharm Sci. 2023;180:106315.","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"3823_CR17","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1080\/14740338.2020.1805431","volume":"19","author":"K Sridharan","year":"2020","unstructured":"Sridharan K, Hasan HM, Al Jufairi M, Al Daylami A, Al Ansari E, Qader AM, Pasha SAA. Possible effects of excipients used in the parenteral drugs administered in critically ill adults, children, and neonates. Expert Opin Drug Saf. 2020;19(12):1625\u201340.","journal-title":"Expert Opin Drug Saf"},{"key":"3823_CR18","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.2147\/OPTH.S382497","volume":"16","author":"S Jandrokovi\u0107","year":"2022","unstructured":"Jandrokovi\u0107 S, Vidas Pauk S, Le\u0161in Ga\u0107ina D, Skegro I, Tomi\u0107 M, Masnec S, Kuzman T, Kalauz M. Tolerability in Glaucoma patients switched from preserved to preservative-free prostaglandin-timolol combination: a prospective real-life study. Clin Ophthalmol. 2022;16:3181\u201392.","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"3823_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/thx.36.8.571","volume":"36","author":"EH Walters","year":"1981","unstructured":"Walters EH, Parrish RW, Bevan C, Smith AP. Induction of bronchial hypersensitivity: evidence for a role for prostaglandins. Thorax. 1981;36(8):571\u20134.","journal-title":"Thorax"},{"issue":"5","key":"3823_CR20","doi-asserted-by":"publisher","first-page":"e22293","DOI":"10.1096\/fj.202101908R","volume":"36","author":"R Zeng","year":"2022","unstructured":"Zeng R, Liu B, Guo T, Guo J, Yu G, Xu Y, Lin R, Tan X, Xie K, Zhou Y. Prostaglandin F2\u03b1 evokes vasoconstrictor and vasodepressor activities that are both independent of the F prostanoid receptor. FASEB J. 2022;36(5):e22293.","journal-title":"FASEB J"},{"issue":"3","key":"3823_CR21","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/sj.eye.6700351","volume":"17","author":"MS Rajan","year":"2003","unstructured":"Rajan MS, Syam P, Liu C. Systemic side effects of topical latanoprost. Eye (Lond). 2003;17(3):442\u20134.","journal-title":"Eye (Lond)"},{"issue":"11","key":"3823_CR22","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.4103\/ijo.IJO_2039_20","volume":"68","author":"L Chakrabarty","year":"2020","unstructured":"Chakrabarty L. Systemic side effects of topical prostaglandin analogues: rare but real. Indian J Ophthalmol. 2020;68(11):2637\u20138.","journal-title":"Indian J Ophthalmol"},{"key":"3823_CR23","unstructured":"Yow AG, Rajasurya V, Ahmed I et al. Sudden Cardiac Death. [Updated 2024 Mar 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507854\/"},{"issue":"30","key":"3823_CR24","doi-asserted-by":"publisher","first-page":"e16597","DOI":"10.1097\/MD.0000000000016597","volume":"98","author":"W Tang","year":"2019","unstructured":"Tang W, Zhang F, Liu K, Duan X. Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: a meta-analysis. Med (Baltim). 2019;98(30):e16597.","journal-title":"Med (Baltim)"},{"issue":"9","key":"3823_CR25","first-page":"1001","volume":"25","author":"JH Heo","year":"2019","unstructured":"Heo JH, Rascati KL, Wilson JP, Lawson KA, Richards KM, Nair R. Comparison of Prostaglandin Analog treatment patterns in Glaucoma and ocular hypertension. J Manag Care Spec Pharm. 2019;25(9):1001\u201310.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03823-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-024-03823-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03823-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T08:02:45Z","timestamp":1735632165000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-024-03823-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3823"],"URL":"https:\/\/doi.org\/10.1186\/s12886-024-03823-w","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"31 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out with the reported data available in public domain and does not require ethics approval as stipulated in the guidelines to applicants for the approval of health research in human subjects by the Ministry of Health, Kingdom of Bahrain. Informed consent is not applicable as there was no involvement of any human subjects in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"554"}}